Sarepta on go with early-stage study of gene therapy GALGT2 for DMD; shares up 1% premarket – Seeking Alpha
|
Sarepta on go with early-stage study of gene therapy GALGT2 for DMD; shares up 1% premarket
Seeking Alpha Sarepta Therapeutics (NASDAQ:SRPT) is up 1% premarket on light volume on the heels of its announcement that the FDA has signed off on its IND for gene therapy GALGT2 for the potential treatment of Duchenne muscular dystrophy (DMD). A Phase 1/2a … |
